Hammarskiöld advised Allarity Therapeutics in connection with the company’s recapitalisation, share-exchange and PIPE investment by PE-fund 3i LP, followed by de-listing from Nasdaq Stockholm and listing on U.S. Nasdaq Stock Market. Investment value approx. SEK 200 million.
Allarity Therapeutics is a clinical-stage biopharmaceutical company specialised in improving cancer patients’ lives by developing novel oncology therapeutics medicines using its Drug Response Predictor (DRP®) technology.
Hammarskiöld’s team consisted of
Jakob Falkman (Partner)
Carl-Johan Pousette (Partner)
Aksel Ahlqvist (Associate)